Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced participation in three virtual investor conferences. Morgan Stanley Global Healthcare Conference will be held on September 15, 2020, featuring CEO Bruce Cozadd. The Cantor Global Healthcare Conference follows on September 16, 2020, also with Cozadd. Lastly, the BofA Global Healthcare Conference on September 18, 2020 will have President Daniel Swisher presenting. Live webcasts will be accessible on the company website, with archives available for a week post-event.
Jazz Pharmaceuticals announced the presentation of 10 abstracts at Virtual SLEEP 2020, the annual meeting of the Associated Professional Sleep Societies, from August 28-30. These presentations showcase significant advancements in sleep medicine, particularly research related to Xywav™ (JZP-258), aimed at treating narcolepsy. Key highlights include studies on health-related quality of life and dose titration in narcolepsy patients. The event features ongoing research on innovative therapies for chronic sleep disorders, emphasizing Jazz's commitment to improving patient outcomes.
Jazz Pharmaceuticals announced its Q2 2020 financial results, showcasing a total revenue increase of 5% year-over-year to $562.4 million. Key highlights included a net income of $114.8 million, though down from $261.9 million in Q2 2019. The company reported strong sales in its neuroscience segment, with Xyrem sales rising 8% to $446.8 million. The FDA approval of Xywav and successful launch of Zepzelca within six months were pivotal moments. Additionally, Jazz updated its financial guidance, projecting 2020 revenues between $2.225 billion and $2.325 billion, marking an increase from earlier estimates.
Jazz Pharmaceuticals announced the FDA approval of Xywav on July 21, 2020, for treating cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy aged 7 and older. Xywav features a unique formulation with 92% less sodium than standard sodium oxybate, which may help patients comply with daily sodium intake recommendations. The approval is based on a Phase 3 clinical study involving 201 patients, showing significant efficacy in reducing cataplexy attacks and improving sleepiness scores. Xywav will launch by the end of the year following implementation of a Risk Evaluation and Mitigation Strategy (REMS).
Jazz Pharmaceuticals announces FDA approval of Zepzelca (lurbinectedin) for treating metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy failure. The accelerated approval is based on a clinical study demonstrating a 35% overall response rate (ORR) and a median response duration of 5.3 months. Zepzelca will be available in the U.S. by early July 2020, following a licensing agreement with PharmaMar, effective January 2020. The treatment offers a new option for patients with limited choices, although continued approval depends on further trials confirming its clinical benefits.